DE3317280A1 - Mittel und dessen verwendung zur behandlung der kahnbein-erkrankung bei pferden - Google Patents
Mittel und dessen verwendung zur behandlung der kahnbein-erkrankung bei pferdenInfo
- Publication number
- DE3317280A1 DE3317280A1 DE19833317280 DE3317280A DE3317280A1 DE 3317280 A1 DE3317280 A1 DE 3317280A1 DE 19833317280 DE19833317280 DE 19833317280 DE 3317280 A DE3317280 A DE 3317280A DE 3317280 A1 DE3317280 A1 DE 3317280A1
- Authority
- DE
- Germany
- Prior art keywords
- isoxsuprine
- horses
- treatment
- bone disease
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 4
- 238000011282 treatment Methods 0.000 title claims description 21
- 241000283086 Equidae Species 0.000 title claims description 20
- 201000010099 disease Diseases 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960004819 isoxsuprine Drugs 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract 2
- 210000003189 scaphoid bone Anatomy 0.000 claims description 16
- NKQVYJRZBVRXRU-UHFFFAOYSA-N 2-methyl-2-(methylamino)propanenitrile Chemical compound CNC(C)(C)C#N NKQVYJRZBVRXRU-UHFFFAOYSA-N 0.000 claims description 14
- 229960004164 isoxsuprine hydrochloride Drugs 0.000 claims description 14
- 208000020084 Bone disease Diseases 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000005662 Paraffin oil Substances 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims 2
- 235000013339 cereals Nutrition 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- SMYHRJOQEVSCKS-UHFFFAOYSA-N methyl 4-hydroxybenzoate;propyl 4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1 SMYHRJOQEVSCKS-UHFFFAOYSA-N 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 abstract description 8
- 239000000654 additive Substances 0.000 abstract 1
- 239000002304 perfume Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 208000030175 lameness Diseases 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- AQKACENWDQZESU-PBOULFJWSA-N (2E,4E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)-hepta-2,4-dienamide Chemical compound CC(C)CNC(=O)\C=C\C=C\CCC1=CC=C2OCOC2=C1 AQKACENWDQZESU-PBOULFJWSA-N 0.000 description 1
- HPSNBOLYHJERIY-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 HPSNBOLYHJERIY-UHFFFAOYSA-N 0.000 description 1
- 206010060964 Arterial haemorrhage Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011283 initial treatment period Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU13906/83A AU552473B2 (en) | 1982-06-18 | 1982-06-18 | Method of treating navicular disease in horses using isoxsuprine hydrochloride |
| AUPF449382 | 1982-06-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3317280A1 true DE3317280A1 (de) | 1983-12-22 |
| DE3317280C2 DE3317280C2 (enrdf_load_stackoverflow) | 1987-12-23 |
Family
ID=25615323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19833317280 Granted DE3317280A1 (de) | 1982-06-18 | 1983-05-11 | Mittel und dessen verwendung zur behandlung der kahnbein-erkrankung bei pferden |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3317280A1 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0140398A1 (en) * | 1983-08-10 | 1985-05-08 | Duphar International Research B.V | Method of orally administering a composition to horses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1218102A (en) * | 1968-03-15 | 1971-01-06 | Philips Nv | Improvements in medicaments comprising drug/ion-exchange resin compounds |
-
1983
- 1983-05-11 DE DE19833317280 patent/DE3317280A1/de active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1218102A (en) * | 1968-03-15 | 1971-01-06 | Philips Nv | Improvements in medicaments comprising drug/ion-exchange resin compounds |
Non-Patent Citations (2)
| Title |
|---|
| Rote Liste, 1976, Aulendorf, Editio Cantor, Nr. 36004B * |
| Rote Liste, 1980, Aulendorf, Editio Cantor, Nr. 36005B u. 36025B * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0140398A1 (en) * | 1983-08-10 | 1985-05-08 | Duphar International Research B.V | Method of orally administering a composition to horses |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3317280C2 (enrdf_load_stackoverflow) | 1987-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69901396T2 (de) | Zusammensetzung enthaltend beta-hydroxy-beta-methylbutyratsäuere und mindestens ein aminosäure | |
| DE69008476T2 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose. | |
| DE2953334C1 (de) | 3-(2,2,2-Trimethylhydrazinium)propionat,Verfahren zu dessen Herstellung und Futtermittel,welche dieses enthalten | |
| DE3709621A1 (de) | Therapeutisches mittel | |
| DE69129115T2 (de) | Neues verfahren zur behandlung von depression | |
| DE3786893T2 (de) | Piperidinderivat zur Schmerzbehandlung. | |
| DE2841668A1 (de) | Medikiertes tierfutter auf basis lebermehl | |
| DE3137125C2 (enrdf_load_stackoverflow) | ||
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE2732175A1 (de) | Oxytocin-analoga, ihre herstellung und pharmazeutische mittel | |
| DE69825605T2 (de) | Behandlung der schizophrenie und der psychose | |
| DE69623074T2 (de) | Methoden um Knochenschwund zu minimieren | |
| DE69131398T2 (de) | Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall | |
| DE3129123A1 (de) | "arzneimittel zur senkung des cholesterinblutspiegels" | |
| EP1397128B1 (de) | Kappa-opiatagonist für die behandlung der reizblase | |
| DE69930624T2 (de) | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie | |
| DE3317280A1 (de) | Mittel und dessen verwendung zur behandlung der kahnbein-erkrankung bei pferden | |
| DE19815411A1 (de) | Thermogenese stimulierend wirksame Arzneimittel | |
| DE2633891C2 (de) | Tris-(hydroxymethyl)-aminomethansalz der 2-(5-Benzoylthienyl)-α-methylessigsäure, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen | |
| DE2823268C2 (enrdf_load_stackoverflow) | ||
| DE60316775T2 (de) | Kombinationspräparat aus epothilone derivate und imidazotetrazinone | |
| DE2820808A1 (de) | Arzneimittel mit einer antanginoesen wirksamkeit | |
| DE1667903B2 (de) | Verwendung von Cysteinderivaten zur Herstellung von per oral verabreichbaren Mitteln zur Bekämpfung der Seborrhoe | |
| DE69001540T2 (de) | Arzneimittel zur rektalen verabreichung von calcitonin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |